This study aims to construct a structuralized follow-up model for survivors of childhood hematological malignancies in China. Using a multicenter prospective cohort design, it will identify the burden and risk factors of late effects. The study hypothesizes that a standardized follow-up path managed by an electronic platform will improve follow-up compliance and reduce the missed diagnosis rate of late effects.
Diagnosed with childhood hematological malignancies (ALL, AML, Lymphoma, etc.), Completed primary treatment for ≥12 months.
Age 1-21 years.
Capable of completing follow-up and data collection.
Informed consent signed.
Severe organ failure preventing follow-up.
Major genetic or systemic diseases affecting growth/organ function.
Expected poor compliance or refusal to participate.
Long-term survivors of childhood hematological malignancies (including ALL, AML, and lymphoma) who have completed primary treatment for at least 12 months and are in complete remission (CR).
Cohort
Prospective
Not listed
Incidence of severe late-effect composite endpoint.
The incidence of grade 3-5 chronic health conditions, including severe cardiovascular events (e.g., heart failure), new-onset diabetes, pathological fractures, severe cognitive/psychological impairment, and second primary malignancies.
Compliance rate of the structured follow-up mode.
The percentage of participants who complete the scheduled follow-up visits and examinations according to their assigned risk level. The target compliance rate is ≥80%.
Click on the lead sponsor to view all of their trials.
The Children's Hospital of Zhejiang University School of Medicine
Lead sponsor
Ningbo Women & Children's Hospital
Collaborator
Hangzhou Children's Hospital
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
